Health Check: A ‘manageable headwind' as Trump slugs Europe with 15pc pharma tariff
Mach 7's new CEO wants to walk in customers' shoes
Highlights from the quarterly reporting fiesta
The European drug sector is exhaling a sigh of relief after the Trump administration's decision to include drugs in a sweeping 15% tariff on European goods.
The Orange One had threatened drug imposts of up to 200%.
In a statement, European Commission President Ursula von der Leyen confirmed pharma products would be included.
The White House Fact Sheet – no, not alternative facts – describes a 15% tariff 'including on autos and auto parts, pharmaceuticals and semiconductors'.
The process is subject to a so-called Section 232 investigation, which examines any national security implications. This is due to conclude on August 1.
Endpoints News reports that the European Union exported US$212 billion of pharma products in 2024. These drugs include Botox, Keytruda and Ozempic.
Ireland accounted for nearly a quarter of these shipments.
Analysts at US investment bank TD Cowen dub the 15% tariff a 'manageable headwind'.
Makers of branded drugs will fare better than generic providers, because of higher prices.
Meanwhile Australian pharma companies are waiting to see how munificent the Prez is – or otherwise.
Federal Health Minister Mark Butler notes the US position on drug tariffs has "changed a lot over the last couple of weeks".
Our capitulation on US beef imports might help, but who can read the mind of Donald John Trump?
Mach 7 says major US job is on track
Radiology imager Mach7 Technologies' (ASX:M7T) new CEO Teri Thomas has reassured investors about the progress of a large, delayed contract with the US Veterans Health Administration.
The job is to support the sprawling organisation's National Teleradiology Program.
Mach 7 is part of a five-member consortium, providing its picture archiving and communications systems.
Announcing the contract in July 2023, the company said the phase one rollout potentially was worth $11.7 million over three years, This rises to $47.9 million for the second five-year phase.
The system was meant to have cranked up by December last year and Thomas hopes this will happen later this year.
'It's progressing,' Thomas says. 'It's big, it's complicated and we are one of a number of vendors who need to come together for this solution to go live.'
Quarterly progress
Meanwhile, Mach 7 has chalked up its third successive quarter of positive cash flow, achieving $600,000 for the period and $700,000 for the year.
The US-focused Mach 7 reported June quarter receipts of $8.4 million, 20% lower owing to 'timing differences' (March quarter receipts were 28% higher).
As of June 30, contracted annual recurring revenue stood at $30.2 million, up 1.6% with 'growth from expansions and renewals offset by customer attrition'.
Mach 7 has $23.1 million cash and no debt.
Unusually for a biotech, Mach 7 has been undertaking a share buyback, having acquired $2.2 million of its own shares in the June half.
This reflects management's belief that that Mach 7's modest $100 million market cap undervalues the company.
Mach 7 shares have lost one-third of their value over the last year, including 8% this morning.
In her maiden investor outing, Thomas this morning spoke of 'getting in the mind of customers and chucking on their shoes'.
If Thomas the Tank Engine builds a head of steam, things could turn around quickly.
Aroa affirms current-year guidance
After a barren couple of weeks, we're being deluged with quarterlies – and far too many to scrutinise properly.
As with Mach 7, Kiwi wound repair house Aroa Biosurgery (ASX:ARX) reported its third successive quarter of positive cash flow, of NZ$1.7 million.
The company also managed receipts of NZ$22.5 million, driven by sales of its Myriad range for large complex wounds.
Aroa has guided to revenue of NZ$92-100 million for the year to March 2026, with normalised underlying earnings of NZ$5-8 million.
Cancer imaging house Imagion Biosystems (ASX:IBX) says it's on track to file an Investigation New Drug (IND) application with the FDA in the current quarter.
If the agency grants the IND, Imagion can kick off a clinical trial of its Magsense tech, for breast imaging.
Magsense will be the first imaging tech to use targeted magnetic nanoparticles to tag and detect cancers.
Imagion had June quarter cash outflows of $818,000, taking cash on hand to $883,000.
The company expects outflows to reduce in the current quarter, as it reduces corporate costs.
Clever Culture Systems (ASX:CC5) chief Brent Barnes says 2024-25 has been a 'turning point for the company, resulting in a major milestone towards becoming a sustainable operating business'.
The company now has signed up five big pharma companies for its automated agar plate system APAS Independence. These are for environmental monitoring of sterile drug making facilities.
The company cites a 'sales opportunity' of $40 million, based on existing customers purchasing 60 to 80 units.
Clever Culture recorded receipts of $880,000 and net operating cash outflows of $248,000. Full year flows were positive to the tune of $1.16 million.
Prescient wants some more
On the fundraising front, cancer drug developer Prescient Therapeutics (ASX:PTX) has raised $6.8 million in a share purchase plan (SPP) and will now carry out a follow-on placement.
Usually, companies do the placement before the SPP, but there are no hard and fast rules.
The shares are on trading hold pending the unquantified placement, which will be done at 4 cents per share (an 11% discount).
Prescient's mercifully slimmed-down program focuses on PTX-100, which is in phase II development.
The world's only GGT-1 inhibitor in clinical development, PTX-100 has looked promising in early programs for blood and solid cancers.
Yesterday, PainChek (ASX:PCK) said it had raised $7.5 million in a placement, partly to support a US rollout into the $580 million US nursing market.
The company expects FDA clearance of its digital pain measurement app by early October.
New and existing institutional, high net worth and sophisticated investors supported the raising.
The company said net contracted licences increased to 110,000. Contracted annual recurring revenue came in at $5.4 million (up 10%).
The placement funds also will support the company's rollout of an infant app locally.
FDA U-turns on key drug decision
In more news from our buzzing Washington desk, the FDA has allowed Sarepta Therapeutics to resume selling its Duchenne muscular dystrophy gene therapy to non-wheelchair bound patients.
In response, shares in the Nasdaq-listed Sarepta bounded almost 50% overnight.
The agency decided the death of a Brazilian boy was unrelated to the drug, Elevidys. But two older patients died earlier.
Sarepta still can't supply the drug to non-ambulatory patients.
Despite the share bounce, Sarepta shares still have lost 90% of their value over the last year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sky News AU
19 minutes ago
- Sky News AU
Russia ignores Trump's brutal 10-day threat with violent strikes on Ukraine
US President Donald Trump has issued a firm 10-day deadline to Russian President Vladimir Putin to end the war. Trump issued the threat on his trip back from Scotland, where the president spoke to reporters on Air Force One. 'Ten days from today – then you know we're going to put on tariffs and stuff,' Trump said. 'And I don't know if it's going to affect Russia because he wants to, obviously, probably keep the war going.' 'But we're going to put on tariffs and the various things that you put up; it may or may not affect them, but it could.' According to President Zelensky and regional officials, at least 27 people have been killed in the latest Russian air attacks on Ukraine. The attacks followed Trump's new deadline and continue to escalate the Ukraine-Russia war.
7NEWS
an hour ago
- 7NEWS
Trump says Epstein ‘stole' Giuffre and other young women from Mar-a-Lago spa
US President Donald Trump said Tuesday that Jeffrey Epstein 'stole' young women who worked for the spa at Mar-a-Lago, the latest evolution in his description of how their highly scrutinised relationship ended years ago. One of the women, he acknowledged, was Virginia Giuffre, who was among Epstein's most well-known sex trafficking accusers. Trump's comments expanded on remarks he had made a day earlier, when he said he had banned Epstein from his private club in Florida two decades ago because his one-time friend 'stole people that worked for me'. At the time, he did not make clear who those workers were. The Republican president has faced an outcry over his administration's refusal to release more records about Epstein after promises of transparency, a rare example of strain within Trump's tightly controlled political coalition. Trump has attempted to tamp down questions about the case, expressing annoyance that people are still talking about it six years after Epstein committed suicide while awaiting trial, even though some of his own allies have promoted conspiracy theories about it. Ghislaine Maxwell, Epstein's imprisoned former girlfriend, was recently interviewed inside a Florida courthouse by the Justice Department's No. 2 official, though officials have not publicly disclosed what she said. Her lawyers said Tuesday that she's willing to answer more questions from Congress if she is granted immunity from future prosecution for her testimony. Aboard Air Force One while returning from Scotland, Trump said he was upset that Epstein was 'taking people who worked for me'. The women, he said, were 'taken out of the spa, hired by him — in other words, gone.' 'I said, listen, we don't want you taking our people,' Trump said. When it happened again, Trump said he banned Epstein from Mar-a-Lago. Asked if Giuffre was one of the employees poached by Epstein, he demurred but then said 'he stole her'. The White House originally said Trump banned Epstein from Mar-a-Lago because he was acting like a 'creep'. Giuffre died by suicide earlier this year. She claimed that Maxwell spotted her working as a spa attendant at Mar-a-Lago in 2000, when she was a teenager, and hired her as Epstein's masseuse, which led to sexual abuse. Although Giuffre's allegations did not become part of criminal prosecutions against Epstein, she is central to conspiracy theories about the case. She accused Epstein of pressuring her into having sex with powerful men. Maxwell, who has denied Giuffre's allegations, is serving a 20-year-prison sentence in a Florida federal prison for conspiring with Epstein to sexually abuse underage girls. A spokeswoman for the House Oversight Committee, which requested the interview with Maxwell, said the panel would not consider granting the immunity she requested. The potential interview is part of a frenzied, renewed interest in the Epstein saga following the Justice Department's July statement that it would not be releasing any additional records from the investigation, an abrupt announcement that stunned online sleuths, conspiracy theorists and elements of Trump's political base who had been hoping to find proof of a government coverup. Since then, the Trump administration has sought to present itself as promoting transparency, with the department urging courts to unseal grand jury transcripts from the sex-trafficking investigation and Deputy Attorney General Todd Blanche interviewing Maxwell over the course of two days at a Florida courthouse last week. In a letter Tuesday, Maxwell's attorneys said that though their initial instinct was for Maxwell to invoke her Fifth Amendment right against self-incrimination, they are open to having her cooperate provided that lawmakers satisfy their request for immunity and other conditions. But the Oversight Committee seemed to reject that offer outright. 'The Oversight Committee will respond to Ms. Maxwell's attorney soon, but it will not consider granting congressional immunity for her testimony,' a spokesperson said. Separately, Maxwell's attorneys have urged the Supreme Court to review her conviction, saying she did not receive a fair trial. They also say that one way she would testify 'openly and honestly, in public', is in the event of a pardon by Trump, who has told reporters that such a move is within his rights but that he has not been not asked to make it. 'She welcomes the opportunity to share the truth and to dispel the many misconceptions and misstatements that have plagued this case from the beginning,' they said.
Perth Now
an hour ago
- Perth Now
Epstein 'stole' Virginia Giuffre from Mar-a-Lago: Trump
US President Donald Trump says Jeffrey Epstein "stole" young women, including Virginia Giuffre, who worked for the spa at his Mar-a-Lago resort. The acknowledgement is the latest evolution in Trump's description of how his highly scrutinised relationship with Epstein ended years ago. Trump's comments expanded on remarks when he said he had banned Epstein from his private club in Florida two decades ago because his one-time friend "stole people that worked for me." At the time, he did not make clear who those workers were. The president has faced an outcry over his administration's refusal to release more records about Epstein after promises of transparency, a rare example of strain within Trump's tightly controlled political coalition. Trump has attempted to tamp down questions about the case, expressing annoyance that people are still talking about it six years after Epstein died by suicide while awaiting trial. Aboard Air Force One while returning from Scotland, Trump said he was upset Epstein was "taking people who worked for me." The women, he said, were "taken out of the spa, hired by him - in other words, gone." "I said, listen, we don't want you taking our people," Trump said. When it happened again, Trump said he banned Epstein from Mar-a-Lago. Asked if Giuffre was one of the employees poached by Epstein, he demurred but then said "he stole her." The White House originally said Trump banned Epstein from Mar-a-Lago because he was acting like a "creep." Giuffre died by suicide earlier this year. She claimed that Ghislaine Maxwell spotted her working as a spa attendant at Mar-a-Lago in 2000, when she was a teenager, and hired her as Epstein's masseuse, which led to sexual abuse. Although Giuffre's allegations did not become part of criminal prosecutions against Epstein, she is central to conspiracy theories about the case. She accused Epstein of pressuring her into having sex with powerful men. 1800 RESPECT (1800 737 732) National Sexual Abuse and Redress Support Service 1800 211 028 Lifeline 13 11 14 beyondblue 1300 22 4636
